A summary of safety letters sent to healthcare professionals in August 2016
In August 2016, a letter was sent to relevant healthcare professionals to inform them of the outcome of a review of the safety of idelalisib (Zydelig▼), including the risk of infection.
See also a Drug Safety Update article on the outcome of the safety review.
Article citation: Drug Safety Update volume 10 issue 2, September 2016: 4.
15 September 2016
Medicines and Healthcare products Regulatory Agency
Don’t include personal or financial information like your National Insurance number or credit card details.